Enzyme reagent MF-UCH-0060

for researchdiagnostic

For rapid quantifying ubiquitin C-terminal hydrolase L1(UCH-L1) by ImmunoMagnetic Reduction (IMR). Features: Quantifying UCH-L1 in the sample easily, rapidly, and accurately Magnetic Nanoparticle Dextran layer For traumatic brain injury and Alzheimer’s disease research and for in-vitro diagnosis use Description Intended Use “MagQu” UCH-L1 IMR Reagent is used to quantitatively measure ubiquitin C-terminal hydrolase L1(UCH-L1) in human fluid specimen, such as plasma, serum or CSF. Use “MagQu” UCH-L1 IMR Reagent only with the XacPro-S System (MagQu Co., Ltd.). Introduction Ubiquitin C-terminal hydrolase L1 (UCH-L1) is an extremely abundant deubiquitinating enzyme in brain, which involved in the elimination of misfolded proteins. UCH-L1 is not essential for neuronal development, but is necessary for maintenance of integrity. Recent studies have found an association between UCH-L1 dysfunction and neurodegenerative diseases. In previous studies, UCH-L1 expression was found to be decreased in patients with ischemic injury and Alzheimer's disease. It is possible that UCH-L1 increases free ubiquitin expression by promoting ubiquitination and accelerates lysosomal degradation of amyloid β-synuclein or α-synuclein, which tend to accumulate when they are reduced. Over-expression of UCH-L1 has also been shown in mouse models to effectively delay the progression of Alzheimer's disease. Thus, UCH-L1 may be a pre-dementia process with the potential to predict the onset of dementia. Principle of Test “MagQu” UCH-L1 IMR Reagent is designed for rapid quantifying UCH-L1 by ImmunoMagnetic Reduction (IMR).